Podcasts about mounjaro

durée : 00:02:54 - L'Humeur du matin par Guillaume Erner - par : Guillaume Erner - Je suis resté songeur devant cette couverture de L'Express. La millième, sans doute, consacrée aux médicaments du XXIᵉ siècle : Ozempic, Mounjaro, et toute cette pharmacopée miracle censée nous faire fondre. - réalisation : Félicie Faugère

What No One Tells You About Life After GLP-1 Meds GLP-1 medications like Ozempic, Wegovy, and Mounjaro have changed the game for weight loss—but what happens when the prescription ends and you need a plan? This week, I'm joined by Dr. Jim Hill, leading obesity researcher and architect of the National Weight Control Registry, to uncover what really happens after GLP-1s—and how to maintain your results without spiraling into regain. We'll explore the three types of weight regain, what makes maintenance so different from weight loss, and why your body is capable of mimicking GLP-1 effects naturally—if you know how to support it. Whether you're on these meds now, thinking of stopping, or just want to protect your progress, this is a must-listen.

Can you get rhabdomyolysis (rhabdo) from taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro(tirzepatide)? Here are the reports of people getting rhabdo after taking these medications, including how much they took, how high their creatine kinase level were, and what happened. Rhabdo after taking glucagon-like peptides appears to be rare but this is still a side effect people should be aware of. View the video below to see the reports yourself.Referencehttps://youtu.be/NlLTIsXJ860 Read My Rhabdo BookAmazon https://amzn.to/4aRPnu4 (affilate link) Consultations https://supplementclarity.com/private-consultations/  Connect With MeaffiliateSupplementClarity.comYouTubeTiktok   About  I've been sorting nutrition facts from fiction since the 1990s and helping people understand dietary supplements, using clinical research as my litmus test. I am unbiased. I analyze the research so you don't have to.  I wrote the first book about exercise-induced rhabdomyolysis.I have an MS in exercise science and a BS in biology & chemistry.   Disclaimer Episodes are for information only. I'm NOT a medical doctor. NO medical advice is given or implied. ALWAYS consult your physician for the best health advice for you. I participate in theAmazon Associates program which means if you click on a link to amazon and make a purchase, I may make a small commission at no extra cost to you.

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. This week's Friday Five tackles a question many women quietly wonder about: “What should I expect if I restart Mounjaro after pregnancy and breastfeeding?”Whether you paused your GLP-1 for pregnancy, breastfeeding, or simply life circumstances, coming back to it after many months brings up a lot of unknowns. In this episode, I break down what typically happens, what we actually know from emerging research, and most importantly—why postpartum women need close, compassionate medical support.Inside the episode, we explore:1. What current guidelines say about GLP-1s, pregnancy, and breastfeedingThe traditional recommendation is stopping GLP-1s two months before trying to conceive and waiting until you're done breastfeeding to restart. But I also share a recent small study looking at semaglutide and its transfer into breast milk—and what that means (and doesn't mean) for real-life decisions.2. Why restarting after long-term use often looks differentIf you were previously on Mounjaro for 6–24 months, your body typically:tolerates the medication more easilycan often titrate up more quicklyexperiences fewer early side effects Some of this is physiologic, some behavioral—because you've already learned hydration, fiber strategies, and the day-after-injection do's and don'ts.3. The postpartum period is the “fourth trimester”—and it changes everythingExhaustion, unpredictable schedules, stress, hormones, sleep deprivation… postpartum is not just a season. It's a vulnerable season. This is why you should never “go cowboy alone” when restarting medication. A skilled clinician helps prevent:excessive restrictionmetabolic overwhelmworsening moodtipping into depression or anxietyextreme titration that backfires4. How ongoing support during pregnancy impacts your restartI share examples from my own clinic: Some women stay with me through pregnancy—not for weight loss, but for structure, nutrition support, and a stable relationship with food. Those women often find it much easier to restart postpartum because they never disconnected from caring for their bodies.5. The good news: most women feel relief when they restartOnce medically cleared and supported, many women say:their appetite becomes manageable againtheir mental load decreasestheir urges and cravings quiet downthey finally feel like they have helpAnd that's the whole point: to feel supported, not stressed.If you're in this season, I'm rooting for both your health and your baby's health. Postpartum is not a time to go it alone, and you deserve expert guidance every step of the way.I hope this episode gives you clarity, comfort, All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Health is the best gift you can give. Select ‘Give as a gift' at checkout to share one of our programs with someone you love. Explore the details here.Support the show

You've seen it all over social media. Everyone's talking about GLP-1's. Maybe you've heard the brand names—Ozempic, Wegovy, Mounjaro—and wondered, "What exactly is this, and why are so many women suddenly using it?" If you're in perimenopause and noticing weight gain despite doing everything "right," battling constant cravings, or feeling like your body is working against you... this episode is for you.Dr. Katashia is back on the podcast to break down exactly what GLP-1's are, how they work, and why they might be a game-changing tool for women navigating the hormonal chaos of midlife. She shares her own experience using them at 48, the side effects you need to know about, and the critical steps to take before you even consider starting. This isn't about taking shortcuts—it's about understanding your options and finally getting the support your body needs during this transition.In this episode we explore:The real purpose of your inner autumn — and how ignoring it creates hormone chaosWhat happens when you stop pushing through PMS and start listening to your bodyHow I cycle sync my entire business with the inner seasonsA behind-the-scenes look at my 2025 autumnTune in next week were we dive into Part 2 of this conversation.Resources:Dr Katashia's Website - drkatashia.comFollow Dr. Katashia on Instagram: @drkatashiaCheck her out on Facebook: Dr. Katashia Wellness CollectiveJoin my Hormone Unfiltered NewsletterAbout KateKate Nguy is the founder of Shee Revival and a Certified Hormone Health Practitioner and Cycle-Syncing Strategist who helps busy women in their 30s and 40s balance their hormones and reclaim their energy. Specializing in the hormonal ups and downs of midlife—from PMS and perimenopause to burnout and cortisol overload—Kate guides women to feel at home in their bodies and live in sync with their natural cycles.. Through cycle syncing, hormone hacks, and nervous system regulation, Kate empowers women to rebalance their hormones, reconnect to their bodies, and revive the vibrant, grounded version of themselves underneath the overwhelm.Tune in now and join the movement toward better hormone health!Follow me @hormoneswithkate on Instagram for more insights, tips, and support!

Dan Lee Lawless returns for his second appearance. We talk about disastrous costume parties (including Dan accidentally turning up as dead Hitler), his ongoing Mounjaro weight-loss journey and its… questionable side effects, Disneyland being the creepiest place on Earth, mascots falling apart emotionally and physically, Sheffield United vs Wednesday chaos.-------------Thanks for listening make sure you follow us on our socials. Sign up to our Patreon where members get an exclusive extra monthly episode plus bonus content.-------------Patreon:https://www.patreon.com/depressedceospodcastLink Tree:https://linktr.ee/depressedceospodcast Hosted on Acast. See acast.com/privacy for more information.

O Mounjaro, medicamento contra diabete utilizado para auxiliar na perda de peso, se transformou no queridinho da classe política em Brasília. Reportagem do UOL mostrou que, no caso do senador Davi Alcolumbre (União Brasil-AP), a origem do medicamento é um empresário foragido da Justiça por envolvimento em um esquema de fraude em combustíveis e lavagem de dinheiro. O empresário é Roberto Augusto Leme da Silva, conhecido como Beto Louco, e está foragido, entre outras coisas, por suspeita de ligação com o Primeiro Comando da Capital, o PCC, maior facção do Brasil. Ele nega. É sobre esse presente de um foragido ao atual presidente do Senado que José Roberto Toledo conversa com o repórter Fabio Serapião, autor da reportagem, no novo episódio do podcast UOL Prime. Nota da defesa: A defesa desconhece os fatos objeto do questionamento. A respeito da inverídica relação de Roberto Leme e Mohamad Mourad com o PCC, são manifestamente equivocadas quaisquer afirmações nesse sentido. Não existe nenhuma evidência probatória que dê liame a essa falsa alegação. #uolprime #PodcastUOLPrime

O Aos Fatos desta quinta-feira (11) destaca a entrevista com o ativista dos direitos humanos sul-africano Albie Sachs, que receberá  o Título Honoris Causa da Universidade Federal da Bahia. Esta edição ainda repercute a capa do Jornal Metropole, que traz a multiplicação das caneta emagrecedoras, impulsionada pela popularização do Mounjaro e Ozempic.

Doctor Mau Informa ®️#drmauinforma 

Send us a textIn this next “Best of 2025” series, I'm bringing back a popular episode featuring my amazing husband, Dr. Taylor Brueseke. Together, we break down Wegovy, Ozempic, and Mounjaro to clear up common misconceptions. Dr. Brueseke explains how these medications work, what they're intended for, and the potential side effects, while I share my personal experience to give you a real-life perspective on using them. Whether you're a healthcare professional, someone navigating your own health journey, or simply curious, this episode will help you better understand these treatments. Let's sort through the confusion and get to the truth about Wegovy, Ozempic, and Mounjaro. Let's dive in!Find show notes at bicepsafterbabies.com/395Follow me on Instagram and Tiktok!Links:Episode 317: I Was Wrong About Wegovy, Ozempic, and Mounjaro with Dr. Taylor Brueseke

Book a FREE functional health discovery call HERE. If you've been hearing the buzz about Ozempic, Wegovy, Mounjaro, or other GLP-1/GIP medications, you're not alone. But there's so much more to this conversation than weight loss. In this episode, Tanya breaks down the real science behind GLP-1 receptor agonists — what they are, how long they've been around, and the growing research that shows benefits far beyond the scale. From heart and kidney protection to inflammation reduction and body composition support, Tanya explains what midlife women need to know before jumping on the bandwagon. She also shares her personal journey exploring micro-dosing peptides (including tirzepatide and NAD+) — what she's learning, what's working, and how she's helping women make informed, safe, and personalized decisions through trusted telemedicine partnerships. Whether you're considering GLP-1s, curious about peptides, or simply trying to build energy and longevity in midlife, this episode will help you understand the research, the real benefits, and the importance of building your health on solid foundations. You'll Learn: What GLP-1 receptor agonists are and how they work in the body The long-term research behind GLP-1s — including heart, kidney, and liver health benefits What “micro-dosing” really means (and what we don't yet know) How peptides like tirzepatide and NAD+ may support energy, inflammation, and recovery Why foundational health habits — nutrition, muscle, rest, stress regulation — matter more than any injection or supplement Practical, real-world takeaways for midlife women seeking sustainable health and vitality Disclaimer: This episode is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare provider before beginning or changing any health protocol or medication.   I hope this episode blesses you! Xoxo, Tanya Episode Resources: Episode Catalog   My trusted Supplement Dispensary: Aligned Vitality Fullscript Dispensary My trusted Telehealth Peptide Provider:  EllieMD_Tanya Engesether *I do get a small commission when you use one of the above affiliate links. 3 Ways To Connect With Me: 1️⃣COACHING: Are you READY to Lead Well, Live Well and BE Well? Book a FREE discovery call with me to find out more about functional health coaching. It's the accountability and guidance you need to reclaim your health and happiness! ➡︎ https://alignedvitalityhealth.com/coaching   2️⃣ FACEBOOK: Become part of our Supportive Facebook Group. Connect, share, and learn with others navigating life and leadership ➡︎ https://alignedvitalityhealth.com/community   3️⃣ CONTACT: Leave me a question or comment ➡︎ https://alignedvitalityhealth.com/contact   "Yes! Finally, a podcast helping others become the thriving leaders they're meant to be outside of hustle-culture! This is an amazing resource! Thank you so much for sharing and helping us become Spirit-driven, peaceful leaders!"    If you can relate, please consider rating and reviewing my show! It helps me reach more people – just like you – to help them change their future. Don't forget to follow the show so you don't miss any episodes! And, if you're feeling really generous, I'd be SO honored if you would share this podcast with someone.   Click here to view our privacy policy.   Reminder:  The information you hear on this show is not meant to diagnose, treat, cure or prevent disease.  It is for educational purposes only. Always consult with your own health practitioner before you make any changes to your health.

Episode Timeline & Main Topics 00:00 — Opening & Community Update • First week doing the podcast fully live thanks to the On The Pen community • Overview of why this week's news is a major turning point in obesity medicine 02:30 — Introducing the “One-and-Done” Obesity Drug (Wave Life Sciences) • WVE-007 early data drops • Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone • Fat loss results and lean-mass increase 06:30 — How Wave-007 Works: INHBE Gene Silencing • Mechanism behind visceral fat reduction • Why this shifts the field toward “quality of weight loss” 09:15 — Why Lean-Mass Preservation Matters • Current GLP-1 medications and muscle loss • Why women dominate trial enrollment and the larger implications • Medicare patients and the coming wave of GLP-1 coverage 13:45 — The Future of Maintenance Therapies • Fractyl Health Revita results • Lilly's orforglipron maintenance design • Why “holding the line” after GLP-1 therapy is the next major category 17:30 — Amylin Agonists: Cagrelintide vs. Eloralintide • Novo's delays and the strategy behind them • Lilly's surprising phase 2 results (up to 20% weight loss) • Combination therapies with tirzepatide or retatrutide 22:30 — FDA Pipeline Acceleration • Potential removal of traditional phase 3 trials • How this speeds up the arrival of next-generation therapies 24:15 — Oral GLP-1 Small Molecules (Structure Therapeutics) • Alaniglipron data and the stock surge • Comparisons to orforglipron and past failures like denuglipron • Why Dave remains skeptical 28:40 — Sponsor Break: Shed & Shapa • Access, coaching, and patient support • Using a numberless scale to build a healthier relationship with weight tracking 31:10 — Counterfeit Ozempic Warning • New fake lot discovered in U.S. pharmacies • How to identify counterfeit pens • Why this should be a national headline • The broader question of drug supply-chain vulnerability 36:00 — Closing Thoughts on the Future of Obesity Medicine • Moving from “more weight loss” to “better weight loss” • Why the field is closer than ever to reshaping obesity as a disease • Gratitude for the community making full-time coverage possible Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

In today's episode, I'm sharing an update I never thought I'd be able to say out loud: it's now around four years since I last ate chocolate, cakes or sweets. I'm talking about where my binge eating started, how sugary foods became my comfort and my reward, and why nothing I tried could touch those cravings for long. I walk you through the turning point during my hypnotherapy training – the deep emotional release that shook my whole body, the work we did on repressed fear, and the specific hypnosis that made chocolate and sweets taste unbearably sweet. From that point on, I simply couldn't eat them in the same way again, and my relationship with food began to shift for good. I also share honestly about choosing to take the Mounjaro jab in 2025 . I explain what it did to my hunger and “food noise”, the side effects I noticed when I increased my dose, the weight I lost, and why I decided to come off it before reaching a final goal weight. This episode is for anyone who feels ruled by cravings, is curious about hypnosis, or worries what life looks like after stopping a weight loss jab.   Get the first 3 modules of “Ease Your Mind” mini-course now for FREE https://www.claireoldhamwest.com/Ease-your-mind

In this episode of Healthy Mom Healthy Baby Tennessee, Dr. Linley Wolfe interviews Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis, about GLP-1 receptor agonist medications (commonly known as Ozempic, Wegovy, and similar drugs) and their implications for pregnancy. The discussion covers how these medications work, their dramatic effects on weight loss and diabetes management, and the emerging phenomenon of "Ozempic babies" - unintended pregnancies occurring in women taking these medications. Dr. Brackney provides guidance on when to discontinue these medications before conception, discusses limited safety data in pregnancy, and explains what monitoring is recommended for women who become pregnant while taking GLP-1s. Both physicians share their personal experiences with these medications and express hope for future research on postpartum use.Episode Highlights00:00:04: Welcome to Healthy Mom, Healthy Baby Tennessee podcast, brought to you by the Tennessee Initiative for Perinatal Quality Care (TIPQC), which exists to improve health outcomes for mothers and infants in Tennessee 00:00:46: Dr. Linley Wolfe introduces Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis who has been practicing as a perinatologist for three years after working as a general OB-GYN for nine years00:01:32: Dr. Brackney describes her passion for caring for women with complex pregnancies and helping them find joy during challenging times00:02:03: Dr. Wolfe introduces the topic of GLP-1 medications, noting they have been revolutionary for people struggling with weight00:02:38: Dr. Brackney explains that GLP-1 receptor agonists work by activating glucagon-like peptide one receptors, regulating blood sugar, reducing appetite, and slowing digestion through multiple mechanisms00:03:46: Discussion of how GLP-1 medications have been around for diabetes treatment but have been increasingly used for weight loss over the last four to five years00:04:04: Dr. Brackney notes these medications are also being used for patients with cardiovascular conditions and kidney disease, showing decreased complications00:04:28: Dr. Wolfe mentions recent approval for people who are overweight with sleep apnea, predicting more indications will emerge00:04:42: Cost identified as one of the biggest barriers to these medications becoming more popular00:05:01: Dr. Brackney reports that semaglutide and tirzepatide show potential for over 10% weight loss, while liraglutide shows 5-15% total weight loss00:05:49: Discussion of side effects, with nausea and constipation being the most common, though they are treatable and many people adjust over time00:06:09: Dr. Wolfe asks about common brand names versus generic names for listener clarity00:06:25: Dr. Brackney lists brand names including Ozempic, Wegovy, Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), and Mounjaro (tirzepatide)00:07:02: Discussion of compounded medications versus manufacturer medications, with Dr. Brackney noting compounded versions are not FDA-regulated and therefore not considered as safe00:07:55: Dr. Wolfe transitions to discussing pregnancy and the phenomenon of "Ozempic babies"00:08:51: Dr. Brackney explains that obesity reduces fertility, with obese women having three times higher risk of infertility and 40% higher miscarriage rates00:10:28: Discussion of how GLP-1 medications may interfere with contraceptive distribution in the body due to slowed gastric emptying00:11:04: Dr. Wolfe summarizes that better overall health, weight loss, and potential contraceptive interference all contribute to "Ozempic babies"00:11:27: Dr. Brackney recommends discontinuing GLP-1 medications at least one to two months before trying to get pregnant, noting limited data on ideal timing00:12:38: Discussion of the lack of...

Professor Michael Barry, Clinical Director for the National Centre for Pharmacoeconomics, on the cost of making the weight loss drug Mounjaro available to public patients.

Los fármacos adelgazantes se han convertido en un fenómeno global. Ozempic sobre todo, pero Wegovy, Mounjaro… son nombres que ya se escuchan por todas partes. Mientras el sobrepeso y la obesidad crecen, también lo hacen los trastornos de la alimentación, la gordofobia y el culto a la imagen. Y quienes pueden permitírselo —porque las dosis de solo un mes pueden costar entre 200 y 400 euros, y el tratamiento puede alargarse muchos— están comprando estos medicamentos, en algunos casos en el mercado negro y sin receta ni necesidad clínica. En plena fiebre por estos medicamentos, la Organización Mundial de la Salud ha publicado una guía que marca cómo deben usarse: ya los clasificaba como esenciales para personas con diabetes, ahora los amplía en casos de obesidad. No los rechaza, para algunas personas pueden ser una herramienta útil, aunque no los indica para todo el mundo ni en ningún caso como tratamiento exclusivo ni sin seguimiento médico. Y advierte de que no pueden quedar solo al alcance de los que tengan el dinero suficiente para pagarlos. Intervienen Mario Fontán, epidemiólogo social y asesor de la Secretaría de Estado del Ministerio de Sanidad, y Lucía Franco, periodista de EL PAÍS que ha investigado el mercado negro de los fármacos adelgazantes y aporta testimonios de vendedores. CRÉDITOS Realiza: Belén Remacha Presenta: Ana Fuentes Diseño de sonido: Nicolás Tsabertidis Coordina: José Juan Morales Dirige: Ana Alonso Edición: Ana Ribera Sintonía: Jorge Magaz Si tienes quejas, dudas o sugerencias, escribe a defensora@elpais.es o manda un audio a +34 649362138 (no atiende llamadas). La OMS reconoce los fármacos adelgazantes como esenciales para la humanidad: “Deben ser accesibles universalmente” De Andorra a Gibraltar, el mercado negro de Ozempic explota su éxito: “Son los productos más demandados del mundo"

For more on this Professor Donal O'Shea, consultant endocrinologist at St. Vincent's University Hospital.

Dr Illona Duffy, GP in Monaghan, and Dr Brian Turner, Health Economist with Cork University Business School

If you've ever wondered what nutrition on a GLP-1 like Ozempic®, Wegovy®, or Mounjaro®, might look like, this episode is for you! Registered dietitian and lead dietitian for the Mayo Clinic Diet®, Tara Schmidt, joins us to share her expertise on why your habits matter just as much as the medication when it comes to weight loss. She shares what she tells her patients about appetite changes, why fatigue often hits around the three-month mark, and what might happen when you stop taking the medication. She also shares her recommendations on protein intake (spoiler: you might need less than you think), and meals that can help keep your energy up, maintaining muscle, and managing side effects like nausea. Care Experts is a weekly podcast by CareCredit where we sit down with doctors and experts who give information, tips and insight into healthcare treatments and procedures. Check in every Wednesday for new episodes at carecredit.com/careexperts or follow on your favorite podcast app. CareCredit is a health, wellness and personal care credit card that has helped millions of people with promotional financing options and is accepted at hundreds of thousands of provider and retail locations nationwide. Learn more at carecredit.com.

Dr. Mindy stops by to talk about Joey's papercut and COVID toes. And then she answers questions about knots, high anxiety in teenagers, long term effects of GLP meds, early menopause, foot pain, warm or cool humidifiers, good bones, Mounjaro options, hysterectomies and stomach issues. https://www.youtube.com/@TheDrMindyExperiment/videosSee omnystudio.com/listener for privacy information.

En este gran episodio, conversamos con Laura Bartolomé, endocrinóloga reconocida, quien nos ofrece una masterclass imprescindible sobre el estado actual de la obesidad, la verdad oculta sobre el "modo ahorro" del cuerpo, y el futuro de los tratamientos contra el exceso de grasa disfuncional¿Por qué la obesidad y el sobrepeso afectan a más del 50% de la población adulta y se consideran una enfermedad crónica, multifactorial y compleja? ¿Cómo actúa el organismo para ponerse en "modo ahorro" y detener la quema de grasa? ¿Son milagrosos fármacos como el Ozempic o Mounjaro y cómo impactan en los circuitos de recompensa del cerebro para controlar el apetito emocional?Abordamos estas y otras preguntas clave para entender la diferencia entre endocrinólogo y nutricionista, cómo tu genética y tus hormonas (como el tiroides o las que cambian en la menopausia) condicionan tu metabolismo, y la importancia del descanso y el ayuno nocturno para mejorar tu composición corporal.¡Disfrutad del podcast!

The cozy, magical season is here! Leggings, sweaters, cookies, hibernation mode. But this can also become the season where we disconnect from our bodies without even realizing it.In this episode, I'm sharing a truth we don't talk about enough:✨ The longer you hide in leggings and oversized sweatshirts, the longer you stay in denial about where you really are physically and emotionally. ✨ Getting dressed, putting on makeup, and wearing a real outfit isn't about vanity… it's about awareness, identity, and showing up for yourself. ✨ And what I don't want is for you to “wake up” in spring only to realize nothing fits and you don't recognize yourself.Let's talk about how you can stay connected, confident, and present with yourself even during cozy season so you don't lose yourself in the process.

Convidados: Bruno Geloneze, endocrinologista e pesquisador da Unicamp, e Henderson Fürst, diretor da Sociedade Brasileira de Bioética. Na semana passada, uma operação da Polícia Federal mirou um esquema ilegal de produção de canetas usadas para emagrecimento. No Brasil, apenas um laboratório tem autorização para vender a Tirzepatida (princípio ativo do Mounjaro) em larga escala. Mas o remédio pode ser feito em farmácias manipuladas, para que médicos ajustem a dose exata para pacientes com necessidades específicas. No esquema investigado pela PF, o médico produzia Tirzepatida em larga escala, sem seguir as regras estabelecidas pela Anvisa. A alta demanda por canetas emagrecedoras manipuladas tem explicação: no caso deste tipo de medicamento, o preço chega a ser metade do valor dos remédios originais, cujas patentes estão em poder de grandes fabricantes. Neste episódio, Victor Boyadjian conversa com o médico endocrinologista Bruno Geloneze e com o advogado Henderson Fürst. Especialista em endocrinologia e metabologia e pesquisador do Centro de Pesquisa em Obesidade e Comorbidades da Unicamp, Geloneze explica quais as diferenças entre os remédios feitos em laboratório e os manipulados. Ele detalha os riscos do uso de canetas emagrecedoras sem saber sua procedência exata e é taxativo: o barato pode sair caro. Diretor da Sociedade Brasileira de Bioética, Henderson fala sobre como um julgamento no Superior Tribunal de Justiça (STJ) nas próximas semanas pode mudar o status das patentes das canetas emagrecedoras no Brasil. Ex-presidente da Comissão de Bioética da OAB, Henderson fala quais seriam os impactos do fim das patentes deste tipo de medicamento e explica quais regras da Anvisa para produção e consumo das canetas estão em vigor.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Boa terça, angulers! Abrimos o #312 comentando a operação que investigou falsificação e comercialização ilegal de Mounjaro. Além disso, conversamos sobre a banalização do uso de canetas emagrecedoras por médicos antiéticos e o aumento da demanda e, portanto, da falsificação desse tipo de medicamento. No segundo bloco, a crise política no entorno da indicação de Jorge Messias ao STF. O Senado está particularmente hostil, mas não somente por isso. No último bloco, nossos pop-ups da semana: o trânsito em julgado do núcleo crucial do golpe; as novas normas para obtenção da CNH; o texto final da COP30; e o fim do tarifaço de Trump para café, carne bovina e outros insumos. Sirva-se! Cortes do episódio em vídeo no @angudegrilo no Instagram e Tiktok! Siga, curta e compartilhe! Edição e mixagem: Tico Pro @ticopro_Redes sociais: Claudio Thorne @claudiothorneCortes em vídeo: Nathália Dias Souza @natdiassouza

Both the Lions and Michigan lose, Eli Zaret joins us as MSU hires Pat Fitzgerald, Tara Reid is a mess, Me-Me-Meghan Markle is a menace, Try Guy Ned Fulmer turns into Cry Guy, and Akaash Singh's wife continues her reign of terror. Eli Zaret joins the show as Michigan falls to the Ohio State Buckeyes, CFB coaching carousel, too much Tom Brady (and why you look different?), MSU's terrible attendance at Ford Field, Jonathan Smith blown OUT, Jordon Hudson at the pump, Michigan basketball wins the Players Era Festival, MSU wins the Fort Myers Tip-Off, the Detroit Lions lose on Thanksgiving, Aidan Hutchinson MIA, Frank Ragnow un-retires and then re-retires, the MLB Winter Meetings, another University of Georgia driving violation, and RIP Fuzzy “Jokester” Zoeller (nice joke, btw). Oh, and Donald Trump nailed a chip shot. The Lions suck, the season is probably over… but Jack White and Eminem rocked the Thanksgiving Halftime show. Drew breaks down the 10 most memorable Thanksgiving Day Halftime Shows. South Park crushed it once again. Ned Fulmer has had a rough time in entertainment recently… so now he turns to his Multiple Sclerosis diagnosis for views. Tara Reid vs YouTuber ‘Sean P'. She's looking great these days. She's totally single now. Why You Look Different?: Kelly Osbourne? Ariana Grande? Kim Mathers? Come out to the Lodge Friday night (9pm – 10pm) to hang with us and support Killer Cares. Amy Schumer is only posting pics of how hot she is thanks to Mounjaro. Hollywood Confidential used our show clips to bash Meghan Markle. Ha ha! She has an As Ever pop-up store at the Soho Home. She has been labeled the ‘Salmonella Sussex'. She'll do anything for a photo op. King Charles wants her to reconnect with Thomas. Akaash Singh's wife remains a human toilet. It's all about Jasleen. Turns out OnlyFans may be problematic for some girls. Jess Brolin is a slob and Drew thinks he looks like Brad Pitt. Gays Against Groomers vs Baltimore teacher James Stilipec. Breaking News: Pat Fitzgerald to MSU. Don't forget to grab your Drew Lane Show merch right here! If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Monday Headline Brief of The Wright Report, Bryan covers the nation's grief and anger after the Washington terror attack, the deepening crisis within America's immigration system, and President Trump's most sweeping border actions yet. He also examines the political backlash, the debate over assimilation, and the global pressures shaping events from Europe to Venezuela. America Mourns and Demands Answers: Staff Sgt. Andrew Wolfe remains in critical condition while Specialist Sarah Beckstrom is laid to rest after last week's terror attack in Washington. DHS confirmed the attacker, Rahmanullah Lakanwal, was a former CIA-backed Afghan Zero Unit fighter who was radicalized after arrival in the United States. Investigators say he drifted between Washington State, Arizona, and the East Coast with little oversight, revealing systemic vetting failures across multiple administrations.   Vetting Breakdown Exposed: Inspector General reports show that over two hundred thousand Afghans brought into the country during the 2021 evacuation were admitted with almost no reliable databases, poor ID verification, and limited interagency cooperation. None received continual vetting after entry. Bryan explains why "strict vetting" is a political myth and why U.S. systems remain unable to verify criminal history, ideology, or cultural fit for many migrants.   Trump Orders the Most Sweeping Immigration Freeze in Decades: The President has paused all asylum applications, halted Afghan visa processing, and instructed his team to permanently pause migration from Third World nations to reset the system. Green card and citizenship requests from nineteen countries are suspended. Trump is also considering the denaturalization of foreign-born citizens who fail loyalty or cultural compatibility standards. Legal scholars note that Section 212(f) of the Immigration and Nationality Act grants the President broad authority to take such steps.   Political Firestorm and Cultural Divide: Republicans and most Independents support a historic crackdown, while Democrats accuse Trump of racism and xenophobia. Some leaders, including Representative Jasmin Crockett and Representative Debbie Wasserman Schultz, blamed the National Guard deployments for the attack. Bryan argues that many progressive lawmakers reject assimilation because they reject the idea of American culture itself, pointing to recent examples in education, media, and politics.   College Degrees Lose Appeal: New polling shows only 33 percent of Americans believe a four-year degree is worth the cost. Interest in vocational training and maritime careers is rising as tuition increases outpace wages. Maritime academies report that graduates earn more than $200,000 a year after six months of work.   The Autopen Controversy: President Trump announced he is canceling all executive actions signed by Joe Biden through the autopen, citing concerns that Biden did not authorize their use. The Justice Department may soon bring cases that will force the Supreme Court to clarify the legality of autopen approvals.   Debate Over Unlawful Orders Heats Up: Reports claim Secretary of War Pete Hegseth ordered a second strike on a cartel boat. Hegseth denies it. Senator Mark Kelly suggested troops should rely on intuition when evaluating orders, which critics warn could lead to chaos and politicized discipline. The issue may shape U.S. operations in the Caribbean.   Global Flashpoints: Venezuela and Europe: Trump rejected demands from Venezuela's Nicolás Maduro for guaranteed amnesty and military control as part of an exit deal. Maduro may attempt a guerrilla resistance if forced out. In Europe, Islamist protests are disrupting Christmas markets in Belgium and Germany, where security costs have surged. France's populist movement is surging in polls as crime tied to migrants fuels public frustration. Portugal's populist party Chega is also now tied for first place in national polling.   Medical News: A major UK study finds that weight loss drugs like Mounjaro and Zepbound must be taken long-term to maintain results, with many patients regaining most of the weight after stopping treatment.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Washington DC terror attack Afghan Zero Unit, Rahmanullah Lakanwal vetting failure, Trump asylum freeze Section 212f, de-naturalization debate immigration reform, Jasmin Crockett Guard criticism, Debbie Wasserman Schultz Trump blame, college degree value drop vocational training, autopen Biden executive actions, Hegseth double tap allegation, Venezuela Maduro exit talks, Belgium Germany Christmas market threats, France National Rally Bardella, Portugal Chega Ventura, GLP-1 weight loss drug study UK

This week Kevin and PJ are feeling fragile as PJ's back is in bits after a yoga class and the lads realise it is probably a blessing they do not have periods because they would absolutely never shut up about it. For the theme they dive into GLP 1s, prompted by the rise of Ozempic and Mounjaro. They chat about their own relationships with their bodies, the way fat people are treated in society and how Irish mothers are far more likely to compliment you on losing five pounds than saving a life.For support around body image, eating disorders, or related concerns, visit BodyWhysSign up to the I'm Grand Mam Patreon for more stunning content ✨ Hosted on Acast. See acast.com/privacy for more information.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Should I take a GLP-1? Real Patient Scenarios and Expert GuidanceTrying to figure out if a GLP-1 medication is right for you can feel overwhelming. With options like Wegovy, Zepbound, Ozempic, and Mounjaro, it's not just about weight—these medications can also support heart health, liver function, sleep, and blood sugar. Understanding who truly benefits takes the guidance of an expert.Joining me today is Danielle Marston, or Dani, a board-certified nurse practitioner specializing in obesity medicine, weight management, and nutrition counseling. Dani holds a certificate of advanced education in obesity medicine through the Obesity Medicine Association and provides comprehensive care at our clinic, Colorado Wake Care at Green Mountain Partners for Health. She's here to explain how GLP-1s work, their benefits, and who they can help the most.Through real patient scenarios and practical advice, Dani shows how obesity care can be personalized, evidence-based, and approachable.Whether you're curious about starting a GLP-1, considering other treatment options, or just trying to understand what's available, this episode gives you a clear roadmap to make informed decisions and find a plan that actually fits your life.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

This episode is sponsored by Welbeck - providing beyond better healthcare Today we're getting into the weighty topic of GLP-1 weight-loss drugs. Ozempic, Wegovy, Mounjaro - it's a hot topic with a story in the news about it every week.   We are delighted to be joined by consultant endocrinologist Dr Saira Hameed who cuts through the noise bringing medical facts and who knows this topic inside and out. In this episode Dr Saira is mythbusting and answering all of your questions and ours about weight loss injections. It's a fascinating episode you won't want to miss. In this episode we discuss: The different drugs on offer Who should and should not be taking them Side effects and health risks Who qualifies for NHS treatment Why honesty is imperative  The moral panic and is it “cheating” to take them. To learn more or book an appointment go to: https://onewelbeck.com/consultants/dr-saira-hameed/ To buy her books: https://amzn.eu/d/3FXSB1B      https://amzn.eu/d/bl86fm0 Get 20% off at LondonNootropics.com with the code SELFCARE If you liked this episode and want to be part of the club, come follow us on all our socials:  To Listen To 40ISH - https://podcasts.apple.com/gb/podcast/40ish/id1757876983 To order our book “HAVE YOU TRIED THIS?” click here - Paperback out now!  https://www.amazon.co.uk/Have-You-Tried-This-Only/dp/1801293139/ref=sr_1_2?crid=1O7EA4ZF1O5CS&keywords=have+you+tried+this&qid=1699449028&sprefix=have+you+tried+%2Caps%2C125&sr=8-2 For Our Exclusive Merch - https://self-care-club.myspreadshop.co.uk/ Join Our Private Facebook Group https://www.facebook.com/groups/1115099072702743/?ref=share_group_link Instagram  https://www.instagram.com/selfcareclubpod/ YouTube https://youtube.com/c/SelfCareClub TikTok https://vm.tiktok.com/ZMLnXyS1S/ Email hello@theselfcareclub.co.uk  Website www.theselfcareclub.co.uk Studio production by @launchpodstudios Music by purpleplanet. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

  As we head towards December, today's episode leans into something many of us are feeling right now: that pull toward more — more deals, more shopping, more pressure, more to-do lists. And yet, beneath all of that, what most of us actually want is much simpler… we want ease. In this episode, I'm talking about the emotional side of Black Friday season, why clutter and chaos in our surroundings often mirror what's happening in our minds, and how easy it is to slip into old habits when life feels heavy. I'm also sharing some very personal updates about my dad's health, the anger I've had to process, and the steps I've taken to protect my own wellbeing during an incredibly stressful few weeks. I've created something new to support anyone who feels mentally overloaded, unfocused, stuck, or simply tired of carrying everything alone: Ease Your Mind — a gentle, simple introduction to hypnosis, with the first three modules completely free. https://www.claireoldhamwest.com/Ease-your-mind It's designed to help you switch off, calm the noise, settle your emotions and finally feel that sense of mental space you've been craving. If you've ever said: “My head's not in it.” “I want to lose weight but I can't focus.” “Stress keeps throwing me off track.” “I don't sleep well and the cravings hit hard.” …this episode is for you. Get the first 3 modules of “Ease Your Mind” mini-course now for FREE https://www.claireoldhamwest.com/Ease-your-mind  

In this weekend deep dive, we break down how a 149-year-old pharma company from Indianapolis reinvented itself through GLP-1 weight-loss drugs like Mounjaro and Zepbound, overtook Novo Nordisk, and became one of Wall Street's hottest stocks. We cover Lilly's history from insulin to Prozac, the explosive growth of its weight-loss franchise, the coming pill that could unlock an even bigger market, and the risks ahead. Is the trillion-dollar valuation just the start, or is the stock already priced for perfection?

Before we all slip into our cozy clothes and head toward the candied yams, I wanted to drop in with a quick Thanksgiving episode and a little love note from my heart to yours.Today, I'm sharing what I'm truly grateful for this season: you. Thank you for listening, for hanging with me through the messy seasons, the comebacks, the pauses, the growth, and all the moments in between. This community means more to me than I can ever put into words.I'm also talking about the real-life chaos of the holidays, the emotional weight many of us carry into this week, and some gentle reminders about food, body image, and giving yourself permission to just be you. You don't need to earn your Thanksgiving meal. You don't need to restrict. You don't need to go overboard. You're allowed to enjoy your plate, be present with your people, and let go of the guilt that diet culture tries to hand you.Take what you need, leave what you don't, and know that you're not alone.Wishing you a happy Thanksgiving filled with yummy food, core memories, and zero shame. I'm so grateful for you. 

BJ never uses his RV. Jamie breaks up with Nile Nile Crocodile. Campbell's VP says soup is made with 3-D printed meat! Black Friday is ruined, as we know it. Mounjaro users put on all the weight they lose.

In this fun, laugh-filled and genuinely eye-opening episode, Michelle Ford sits down with women's health nutritionist Emma Bardwell to tackle one of the most underrated pillars of midlife wellbeing: fibre - the true unsung hero of women's health. Between giggles over “poophoria” (yes, it's a thing!) and some serious myth-busting, Michelle and Emma unpack why getting enough fibre and protein is essential - especially if you're using GLP-1 weight-loss injections like Ozempic, Wegovy or Mounjaro. As Emma explains, these medications slow digestion, making fibre even more important for gut motility, nutrient absorption and long-term health.Forget fibre's dusty, boring reputation - this episode gives it a full glow-up. Through perimenopause and menopause, when hormones fluctuate and the gut becomes increasingly linked to mood, energy and resilience, fibre becomes a midlife powerhouse. Michelle and Emma explore how nourishing your gut supports immunity, mental wellbeing, metabolism and overall vitality, and why our midlife microbiome deserves centre stage. With Emma's straight-talking, practical approach, you'll learn simple, everyday ways to boost your fibre intake - no chia-seed obsession required.By the end, you'll never look at your plate (or your bowel movements!) the same way again.

Weight loss is the modern-day quest for eternal life. But are drugs like Ozempic and Mounjaro the magic formula we've been waiting for, or a dangerous shortcut? In this episode, we sit down with renowned endocrinologist Dr. Ambrish Mithal to separate fact from fiction. We dive deep into the science behind these "miracle" drugs, exploring why weight loss is so hard, the role of our brain and culture in obesity, and the crucial difference between using these medications for cosmetic reasons versus treating a serious health condition. Get a balanced, expert perspective on the side effects, the long-term implications, and who should really consider this path. It's a fascinating conversation that cuts through the noise on one of today's most polarizing topics. 00:00 Highlights of the Episode 03:00 Introducing to Dr. Ambrish Mithal 04:36 The Obsession with Weight Loss 12:47 Cultural Influences on Obesity 14:54 Debunking Weight Loss Myths 19:45 The Role of Continuous Glucose Monitoring 27:13 Natural and Surgical Weight Loss Methods 28:54 The Role of Exercise in Weight Loss 30:06 Strength Training and Muscle Preservation 30:40 Should You Use Weight Loss Drugs? 31:30 The Weight Loss Revolution: Ozempic and Beyond 36:18 Addressing Concerns and Side Effects 40:32 Long-Term Use and Lifestyle Changes 44:32 The Cost and Accessibility of Weight Loss Drugs 47:27 Social Impacts and Final Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

In this conversation, Gianna discusses the role of GLP-1 medications in weight management, emphasizing that they are tools to support individuals in their health journeys rather than shortcuts. She highlights the importance of building habits and how GLP-1s can reduce resistance in the body, making it easier to achieve health goals.TakeawaysGLP-1s are tools that enhance the effectiveness of your efforts.They help build habits without constant struggle.The use of GLP-1s is not a shortcut but a strategic change.They support the body's processes to function more easily.Feeling your best is achievable with the right support.Weight management requires personal effort alongside medication.GLP-1s can reduce friction in health journeys.Building habits is crucial for long-term success.The relief of effective strategies can be rewarding.Support from GLP-1s can lead to better health outcomes.

In this episode, Dr. Taves and Dr. Sarah Thomas explore how GLP-1 weight loss drugs—such as Ozempic, Wegovy, and Mounjaro—may influence headaches and migraines. They break down how these medications work in the body, how blood sugar stability impacts migraine symptoms, and why some people notice improvement while others experience worsening headaches.They also discuss an important but often overlooked consideration: even if GLP-1 medications help with weight loss or migraine symptoms, there may be other factors to think about before relying on them long-term. From side effects to the difference between symptom management and addressing the root cause, this episode helps listeners understand the full picture so they can make informed decisions.Novera: Headache Center

Novo Nordisk, leader européen de la pharma en 2023, a vu sa capitalisation chuter de 63 % en deux ans, dépassé par Eli Lilly et son Mounjaro. La concurrence s'intensifie sur le marché des traitements contre l'obésité, avec l'arrivée attendue de nouveaux acteurs comme Roche et Pfizer. Dans « La Story », le podcast d'actualité des « Echos », Pierrick Fay et Myriam Chauvot reviennent sur la bataille de l'obésité dans l'industrie pharmaceutique, bataille arbitrée aussi par Donald Trump.« La Story » est un podcast des « Echos » présenté par Pierrick Fay. Cet épisode a été enregistré en novembre 2025. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste au service industries des « Echos »). Réalisation : Willy Ganne. Musique : Théo Boulenger. Identité graphique : Upian. Photo : Shutterstock. Sons : BFM Business, Loopsider, extrait « La cité de la peur », extrait «L'aile ou la cuisse», Extrait «Taxi 3». Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr/lastory Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Pharma giant Eli Lilly manufactures the ingredients for its weight-loss drug Mounjaro and its diabetes drug Zepbound in Kinsale, Co Cork.The Irish Fiscal Advisory Council (Ifac) has found that the unprecedented surge in Irish exports this year (exports to the US rose by 153 per cent to €71bn between January and May) was almost entirely driven by shipments of these ingredients.Ifac tracked about €36.4bn of this export surge to Indianapolis, where Eli Lilly is headquartered and where it has several manufacturing sites.The jump in exports is expected to see the Irish economy expand by almost 11 per cent in GDP terms this year, which is almost certain to make it the fastest-growing advanced economy in the world in 2025.So with such an over-reliance on foreign direct investment, notably in the pharma sector, at a time of tariff threats and uncertainty, how vulnerable is Ireland?Irish Times economics correspondent Eoin Burke-Kennedy explains.Presented by Bernice Harrison. Produced by Suzanne Brennan and Andrew McNair. Hosted on Acast. See acast.com/privacy for more information.

After a nasty fall in the garden and a looming operation with added risk due to weight, sleep apnoea and breathing issues, Stephen made a decision. With a nudge from his wife, he walked into our local Slimming World group at 25st 4lb—and everything started to shift. In this chat we cover the real stuff: losing identity after giving up rugby, the stop–start attempts, the “still think fat” moments even as the clothes sizes drop, and the power of a room that claps for your wins (and your wobbles). This is a first for Slimming Stories, I met Stephen at my local Slimming World Group that Wray Annabel had inherited from Sue Redfern, both amazing Slimming World Consultants. Stephen talks about the support he's felt and why weekly accountability beat “I'll do it myself” plans. If you've tried to get back on plan before, drifted, and need a simple proof that consistency + community works. If you've ever felt “I still look the same” while everyone else notices your progress—this one's for you. Timestamps: 00:01:10 The fall that changed everything: shattered shoulder & surgery risks 00:02:20 Sleep apnoea, anaesthetic concerns & his wife's life-saving nudge 00:03:30 Walking into Slimming World for the first time 00:04:15 Starting weight: 25st 4lb — and why it didn't scare him 00:05:10 Early mobility struggles & realising things had to change 00:06:00 Past attempts, shift work & why accountability finally clicked 00:07:15 The moment group support made the journey “stick” 00:08:30 Seeing change vs feeling change — the “still think fat” phase 00:09:40 Clothes sizes dropping: 3XL to 2XL and the mind catching up 00:10:30 All-or-nothing beginnings: no Syns, full focus 00:11:45 Learning balance: reintroducing treats without spiralling 00:12:40 Rugby days, injuries & losing a big part of his identity 00:14:00 Life after sport: stoma, mini-stroke & stepping away for good 00:15:30 Food habits during care work & long days with no meals 00:16:45 The power of routine & regular eating 00:17:30 The Slimming World spark: stickers, shinies & friendly competition 00:18:45 First gains on the scales — and bouncing back stronger 00:20:00 Breaking the old “I've blown it, so I'll binge” pattern 00:21:10 New rules: sad = apple, happy = strawberries 00:22:00 Weight loss milestones month by month 00:23:15 Hitting target in 41 weeks — with holidays included 00:24:10 The freedom of staying in control & losing the fear Wrays Slimming World Groups Mansfield: If you are local to Mansfield and would be interested in attending one of Wrays Slimming World Classes feel free to contact Wray on the following link. https://www.facebook.com/groups/704401220014053

Today's episode is all about the part of weight loss no one talks about enough- the mindset, the habits and the subconscious patterns. We brought on Dr. Molly Lupo, DNP to talk more about the psychology of weight management, because let's be real… most women don't struggle with knowing what to do, they struggle with actually doing it consistently. Dr. Molly has her doctor of nursing practice and has been a nurse practitioner for over 12 years. She specializes in obesity medicine and helps her patients integrate medications with personalized care.Inside this episode, we dive deep into:Why mindset is the missing piece in most weight loss advice and why willpower alone is never the problemHow your thoughts shape your habits, cravings, and behaviors long before you even touch foodThe “hunger panic” loop and how to slow down impulsive eating with tools that actually workThe art of “diffusion,” which is a technique that helps you separate yourself from your cravings instead of obeying themMaking consistency a daily practice Navigating the upcoming holiday season with a weight loss goalConnect with Dr. Molly below:Website is hereInstagram is hereFor more information & to join the Confident Clinician check it out here! Be sure to DM us on Instagram once you become a member for your special gift! Don't forget to follow us on Instagram @girlsgonewellnesspodcast for updates and more wellness tips. You can also subscribe to our Youtube Channel @Girlsgonewellnesspodcast to watch our episodes! Please subscribe to our podcast and leave a review—we truly appreciate your support. Let's embark on this journey to wellness together!DISCLAIMER: Nothing mentioned in this episode is medical advice and should not be taken as so. If you have any health concerns, please discuss these with your doctor or a licensed healthcare professional.

ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon, Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it's diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing.In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.)TOP TEN QUESTIONS What is carcinoid syndrome? Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative, but someone can still have carcinoid syndrome?Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome?For those who have carcinoid syndrome, what additional tests should they have?Why should carcinoid syndrome be treated? What are the possible issues if it is not treated?How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment?Can carcinoid syndrome be prevented or detected early? Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome, such as age, weight or other diseases? You recently published a study discussing the possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug, and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings?ABOUT DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa.  His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs.For more information, visit NCF.net/podcast/49For more information, visit NCF.net.

Ozempic. Wegovy. Mounjaro. If you've ever found yourself wondering, “Should I try one?”—this episode is for you.Roughly 12% of Americans have tried a weight loss drug, yet up to 85% stop within two years. Most regain the weight, and many feel worse than before. So why do these drugs seem so promising—and why don't they work long-term?Today you will learn…- How GLP-1 drugs actually work - The dark side of GLP-1s that no one mentions- What happens when you stop taking weight loss medications - The sustainable alternative to healing food noise

Doctor Mau Informa ®️#drmauinforma Mounjaro (Tirzepatida): ¿Magia o Ciencia?

In this episode, you will learn:What are peptides? The basic science of these "small proteins" and how they signal cells to function.GLP-1s Explained: How drugs like Ozempic and Mounjaro were originally developed for diabetes but have gained popularity for weight loss.The Big Picture: Peptides are used for more than just weight loss—Dr. Jones discusses their use in migraines, bone building, and studies for ALS and MS.The Weight Loss Surge: Why obesity and its link to chronic diseases (diabetes, hypertension, high cholesterol) is fueling interest in these drugs.The Critical Component: Why a GLP-1 shot is not enough—the medication must be combined with good nutrition, exercise, and psychological health for lasting success.Protein is Key: The importance of adequate protein intake and strength training to maintain muscle mass and prevent hair loss associated with rapid weight loss.The Inflammation Link: How GLP-1s can decrease inflammation (like high cortisol) which often causes stubborn abdominal fat and joint pain.Dispelling Myths: Separating real side effects (like minor hypoglycemia) from media fear-mongering (like blindness), and understanding that hair loss is often due to rapid weight loss, not the drug itself.Next Steps: Where to start if you are interested in peptide therapy and the importance of a consult with a pharmacist.Resources Mentioned:Your Health Wellness Team: Contact the team to schedule a consultation on weight loss goals and peptide therapy. www.YourHealth.Org